Fedratinib Hydrochloride and Tipranavir Oral Solution
Determining the interaction of Fedratinib Hydrochloride and Tipranavir Oral Solution and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR CLOSELY: Theoretically, tipranavir may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, high supplemental dosages of vitamin E, or agents that commonly cause thrombocytopenia. Tipranavir has been shown to inhibit human platelet aggregation in vitro at levels consistent with exposures observed in patients receiving tipranavir/ritonavir. Cases of intracranial hemorrhage, some fatal, have been reported during postmarketing use. However, many of these patients had other medical conditions or were receiving concomitant medications that may have caused or contributed to these events. No pattern of abnormal coagulation parameters has been observed in patients in general, or preceding the development of intracranial hemorrhage. MANAGEMENT: Caution is advised if tipranavir/ritonavir is used in combination with other drugs that affect hemostasis. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. References "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.
Professional:MONITOR CLOSELY: Theoretically, tipranavir may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, high supplemental dosages of vitamin E, or agents that commonly cause thrombocytopenia. Tipranavir has been shown to inhibit human platelet aggregation in vitro at levels consistent with exposures observed in patients receiving tipranavir/ritonavir. Cases of intracranial hemorrhage, some fatal, have been reported during postmarketing use. However, many of these patients had other medical conditions or were receiving concomitant medications that may have caused or contributed to these events. No pattern of abnormal coagulation parameters has been observed in patients in general, or preceding the development of intracranial hemorrhage.
MANAGEMENT: Caution is advised if tipranavir/ritonavir is used in combination with other drugs that affect hemostasis. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
- "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.
Generic Name: fedratinib
Brand name: Inrebic
Synonyms: Fedratinib
Generic Name: tipranavir
Brand name: Aptivus
Synonyms: Tipranavir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fedratinib Hydrochloride-Tirofiban
- Fedratinib Hydrochloride-Tirofiban Intravenous
- Fedratinib Hydrochloride-Tirosint
- Fedratinib Hydrochloride-Tirosint-Sol
- Fedratinib Hydrochloride-Tisagenlecleucel
- Fedratinib Hydrochloride-Tisagenlecleucel Intravenous
- Tipranavir Oral Solution-Feiba
- Tipranavir Oral Solution-Feiba NF
- Tipranavir Oral Solution-Feiba VH Immuno
- Tipranavir Oral Solution-Feiba-VH
- Tipranavir Oral Solution-Felbamate
- Tipranavir Oral Solution-Felbamate Oral Suspension